Hepatitis C and Dating

What can you do if you have the Hepatitis C virus and want to have a normal loving relationship? Dating in this day and age is difficult enough but dating when you have the Hepatitis C virus can be even tougher. You might think it is impossible.  If you are fortunate enough to meet someone and begin dating how long before you find it necessary to broach the subject of having Hepatitis C?  That can be a scary thing for those who are not infected. They may not want to take the chance of getting too close to someone who is infected for fear that they themselves could contract the virus. Who wants to go through that kind of rejection?

Then what do you do? No one wants to envisage a life alone. The best alternative is to look into the dating sites that are aimed only at those who have Hepatitis C. With several million sufferers in the Untied States it seems that these dating sites are worth looking into.  There is nothing wrong with visiting these sites. You shouldn't feel funny about it. People are there for the same reason you are, to be seen as a person of worth instead of someone with hepatitis. Maybe you'll find that someone special and maybe not. At the very worst you will meet a bunch of people who will give you understanding and compassion instead of being afraid of you.

There are sites like this all over the world. With over a hundred million sufferers globally there must be some people you can meet who will help to fill that void you feel. Many people who have Hepatitis C stop socializing for fear of a lack of compassion from both old friends and those they may meet.  They feel ostracized and so over time they become lonely, keeping to themselves to avoid the pain of potential rejection.  No one should have to live like that. Not when the opportunity to change all that is opened to you.

These sites also usually offer chat rooms for those times when you are feeling most alone and just want to feel in the company of friends that understand what you are going through. A lot of these dating sites for people with Hepatitis C also offer support groups for this same reason.  It allows an exchange of ideas and the opportunity to listen to advise from others who may have had treatment successes.  As well, it's just nice to share the day's events with people you enjoy talking to.  Maybe you'll meet your should mate, fall in love and never be alone again. Maybe you'll find a lover who is lonely like yourself and that builds to something lasting. Or maybe you just have the opportunity to make some friends to go to the movies with or out for the odd dinner. No matter which one it is it will lessen your loneliness and bring you back into the world of people again.

Hepatitis news on the Web

As death nears, hepatitis C victim to give videotaped deposition in Desai case - Las Vegas Review-Journal

As death nears, hepatitis C victim to give videotaped deposition in Desai case
Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...

and more »

BioLineRx Licenses Another Hepatitis C Drug From Genoscience - Wall Street Journal

BioLineRx Licenses Another Hepatitis C Drug From Genoscience
Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)
BiolineRX signs second hepatitis C licensing dealGlobes

all 24 news articles »

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ... - FierceBiotech

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...
FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...

and more »

Gilead Sciences Jumps on Hepatitis C Data - Pharmaceutical Processing

Gilead Sciences Jumps on Hepatitis C Data
Pharmaceutical Processing
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
Does Anavex Life Sciences (AVXL) Have the Next Big Thing Big Pharma Wants?SmallCap Network
Positive Clinical Trial Results Boost Gilead the Most in Three Years – NASDAQ:GILDGalaxy Stocks
Gilead stock rises on potential hepatitis C cureSan Francisco Business Times (blog)
Proactive Investors USA & Canada -Seeking Alpha -CNBC.com
all 12 news articles »

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead Up 6% After Positive Hep-C TrialWall St. Cheat Sheet
DailyFinance -24/7 Wall St.
all 63 news articles »

Culture: Impact of war on language (155) - Egyptian Gazette

Culture: Impact of war on language (155)
Egyptian Gazette
In several studies of Veteran's Affairs (VA) Medical Centre patients, we find that 8-9% are positive for hepatitis C antibodies. Some VA Medical Centres had 10-20% of patients with hepatitis C antibodies. According to Dr Bradford Waters, Professor of ...

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock DownNASDAQ
PR Newswire (press release)
all 31 news articles »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex Falls as Analyst Cuts Sales Estimates on Hepatitis C PillBloomberg
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
LocalizedUSA -Financial News Network Online
all 15 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge

all 5 news articles »

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ... - Gastroenterology & Endoscopy News

Gastroenterology & Endoscopy News

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ...
Gastroenterology & Endoscopy News
by Christina Frangou A combination therapy including two investigational direct-acting antiviral agents (DAAs)—asunaprevir and daclatasvir—suppressed hepatitis C virus (HCV) genotype 1 infection in a majority of patients who had previously not ...


Google News